FAS gene, a direct target for NFκB transcription factor, is repressed in solid tumors including colon carcinomas. We have previously reported that, while overexpressed in low risk myelodysplastic syndromes (MDS), the Fas death receptor becomes undetectable on CD34 + progenitors when the disease progresses to secondary acute myeloid leukaemia (sAML). This study aimed at investigating the interplay between NFκB and Fas during MDS progression.
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The transformation of MDS to AML is accompanied by the acquisition of mechanisms of resistance to apoptosis, either the upregulation of anti-apoptotic proteins like Bcl2 or the downregulation of pro-apoptotic effectors like Bad (21, 22) . While the forced expression of Bcl2 prevents MDS progenitor apoptosis in vitro (23) , it has been recently shown using the MDS-like NUP98-HOXD13 transgenic mice model that Bcl2 does not stimulate the leukemic transformation (24) . We have previously reported, that Fas receptor was overexpressed at the cell surface of MDS CD34 + progenitors in early diseases while it was downregulated at the time of progression (25) . Furthermore, we also reported that FAS gene silencing in 60% of patients with secondary AML was linked to the epigenetic repression of its transcription (26) .
The aim of the present work was to further investigate the interplay between FAS gene and NFκB during the progression of MDS to AML.
Material and methods

Cell lines, reagents and antibodies
HL-60 and SW-480 human cell lines were cultured in RPMI supplemented with glutamine, 10% fetal calf serum, penicillin-streptomycin (GibcoBRL Life Technologies, Paisley, UK).
Tumor necrosis factor-α (TNF-α) was purchased from R&D Biosystem (Minneapolis, Forty-three patients with a MDS ie 5q-syndrome (n=1), refractory anemia (RA, n=6), refactory cytopenia with multilineage dysplasia (RCMD, n=4), RA or RCMD with ring sideroblasts (RARS or RCMD-RS, n= 9), RA with excess of blasts type 1 (RAEB1, n=11), or type 2 (RAEB2, n=12), or secondary AML (sAML, n=10) and 15 age-matched controls with normal bone marrow (BM) were included between 2005 and 2011, after they gave their informed consent (Table S1 ). This study was approved by the local ethics committee. CD34 + cells were sorted from mononuclear cell populations on magnetic beads (kit MACS, Miltenyi Biotech, Bergisch Badgach, Germany). Purity was controlled by flow cytometry and was always > 85%. Mononuclear cells isolated on Ficoll gradient were maintained in Iscove's modification of Dulbecco medium (GibcoBRL Life Technologies) containing 10% fetal calf serum or 15% bovine serum albumin with insulin and transferrin, 50ng/mL stem cell factor (SCF), 50ng/mL thrombopoietin (TPO), 100ng/mL Flt3-ligand (FLT3L) and 20ng/mL interleukin-6 (IL-6). In some experiments, cells were incubated with 10 ng/mL of TNFα.
Flow cytometry
Membrane Fas expression was quantified by flow cytometry on cell lines or bone marrow
CD45
lo /CD34 + cell population after red blood cell lysis and expressed as ratio of median fluorescence intensity (RFI) between specific to isotypic antibody. Analysis was performed on FC500 TM flow cytometer (Beckman Coulter, Miami, FL) using CXP Analysis software (Beckman Coulter).
Gene expression analysis
RNA from BM mononuclear cell stored in Trizol® (Invitrogen, Carlsbad, CA) or from cell lines was extracted on RNeasy Plus Mini kit (Qiagen, Valencia, CA). The quality was assessed by size fractionation by microfluidics instrument (Agilent Technologies, Palo Alto, CA). One μg RNA was used per reverse transcription reaction using the Superscript2 (Invitrogen). cDNA strand was diluted and conserved at -80°C. Quantitative PCR (qPCR) was performed with a LightCycler® FastStart DNA Master PLUS SYBR® Green I kit on Light 
Immunofluorescence.
Cells were washed in phosphate-buffered saline (PBS) 1X pH 7.4 and cytospined. After treatment with acetone, cell fixation was achieved with 2% PBS-formaldehyde for 20 min.
Then, cells were permeabilized in methanol for 10 min at room temperature, followed by 15 min at 4°C with PBS-Triton 0,2%. After saturation in PBS containing 3% human serum albumin (HSA) for 1 h, cells were incubated with p65/RelA rabbit polyclonal antibody at 1:200 in PBS-HSA 1%-Tween 0,1% over night at 4°C. After washing, cells were incubated with goat anti-rabbit Alexa Fluor 568-conjugated antibody (Molecular Probes, Invitrogen, Carlsbad, CA) at 1:5000 for 40 min at room temperature. Nuclei were stained with diaminido phenylindol (DAPI, Sigma) at 1:1000 for 5 min at room temperature. Images were obtained on a Leica DMB microscope and analyzed using Metamorph software (Molecular Devicer Corp, Dowington, PA). Signals were quantified using ImageJ software (NIH, Bethesda, MY).
Nuclear Extracts and p65/RelA oligoprecipitation
Cells were lysed for 10 min at 4°C in buffer A (10 mM HEPES, pH 7.6, 3 mM MgCl 2 , 10 mM KCl, 5% glycerol, 0.5% NP-40) containing 1 mM Na 2 VO 4 , 20 mM NaF, 1 mM sodium pyrophosphate, 25 mM β-glycerophosphate and proteinase inhibitors (Roche Diagnostics, Mannheim, Germany). After centrifugation, nuclear pellets were extracted in buffer A Table S3 .
Western Blot Analysis
Samples were subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. Filters were blocked overnight in 5% skimmed milk Tris-buffered saline (TBS) pH7.4 0.05% Tween 20 and incubated with the appropriate antibody.
Membranes were washed three times in TBS-Tween 20 and incubated for 1 hour with the appropriate peroxidase-conjugated secondary antibody. 
Lentivirus construction and cell infection
FAS promoter methylation analysis
Sodium bisulfite treatment of genomic DNA was used to convert unmethylated cytosine to uracil by oxidative deamination. Briefly, after treatment with proteinase K, DNA was extracted from cell lines or bone marrow Table S3 . PCR products were purified using the QIAquick PCR Purification kit. For BM CD34 + samples, PCR products were cloned in bacteria using TOPO TA Cloning® kit. Plasmid DNA was extracted and sequenced on ABI Prism 3100 apparatus (Applied Biosystems, Foster City, CA). .
Chromatin immunoprecipitation
Luciferase assay for in vitro measurement of FAS promoter activity
Reporter construction pGL2 FAS-Luc containing the -1519 to + 201 FAS promoter region spanning over the TSS (+1) was a gift from Dr LB Owen-Schaub (MD Anderson, Houston, TX) (19) . 
FAS gene expression is epigenetically regulated
To explain why the recruitment of p65/RelA to the chromatin varied depending on the cell type, we Azacitidine also increased the recruitment of p65/RelA at FAS promoter in SW-480 cell line while it did not modify p65/RelA binding in the HL60 cell line ( Figure 3C, right panel) . We also transfected 293T cells with a pGL2 construct containing the FAS promoter region (-1519 to + 201 over the TSS) in either a methylated or an unmethylated conformation, inserted upstream of the luciferase gene reporter (19) . As shown in Figure 3D , the luciferase activity was increased in cells transfected with the unmethylated FAS promoter construct, thus confirming the regulatory role of DNA methylation on FAS promoter activity. TNFα (10 ng/mL for 6h) further increased the promoter activity that was abrogated by the NFκB inhibitor, BAY11-7082. Altogether, NFκB-dependent FAS gene expression is epigenetically regulated.
NFκB controls Fas expression in MDS/sAML bone marrow mononuclear cells
The clinical relevance of these findings was investigated in primary bone marrow (BM) myeloid cells collected from 53 patients with a MDS (n=43) or a secondary AML (n=10) and 15 healthy controls. Karyotype was unavailable in 7 patients. According to IPSS, 27 MDS patients had a low risk (LR)-MDS and 11 had a high risk (HR)-MDS (Table S1 ). In agreement with our previous data (26) Table S1 ).
Serial samples (n=22) at the time of diagnosis and at the time of progression or transformation were studied for the expression of Fas ( Figure 4A ). In 16 cases at diagnosis, the level of Fas protein was elevated mostly in patients with percentages of BM blasts lower than 10%.
Among those cases, 14 had a significant reduction of Fas level at the time of disease progression to high risk MDS or sAML, except for cases 14 and 28. The Fas RFI was inversely correlated with the percentage of BM blasts.
We then investigated the effect of TNFα on Fas expression. Primary BM mononuclear cells isolated from 4 Fas-negative samples of AML were incubated with 10 ng/mL TNFα for 6 h.
Immuno-localization of p65/RelA was performed and demonstrated the presence of p65/RelA in the nucleus of blast cells at baseline. After treatment with TNFα, we observed an increment of the nuclear expression of p65/RelA in 3 cases (#3, 17, 49), suggesting that NFκB pathway could be activated in these cells ( Figure 4B) . However, Fas expression remained low after treatment with TNFα in the 4 cases both at transcript and protein levels, while Bclx L expression increased in the same 3 cases (Figure 4B ). This suggests that TNFα-stimulated transcription of FAS gene could be specifically abrogated in primary AML cells.
BAY11-7082 decreases Fas expression on MDS/AML bone marrow mononuclear cells.
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down-regulation. Interestingly, this down-regulation is reversible upon azacitidine therapy, leading to FAS gene re-expression.
NFκB can promote cell survival through the transcriptional regulation of IAP (X-IAP, cIAP1
and cIAP2) or Bclx L (BCL2L1) family members or cell proliferation through the up-regulation of CYCD1 and c-MYC (16, 27) . NFκB can also facilitate cell death through the death receptor-mediated extrinsic pathway (19, 20, 27) . These dual pro-and anti-apoptotic functions of NFκB could apply to MDS. In low risk MDS, the NFκB activity, that could be due to (6, 20) , and various solid tumor cell types (11, 32) . The cell context may be essential as NFκB activation through the alternate pathway could be a FAS transcription repressor in MEL cells (34) . Alternatively, the threshold of NFκB activity, which is under control of either the quantity of dimers p65/p65, p50/p50 and p65/p50 recruited to the chromatin, or post-translational modifications, or interactions with other transcription factors like Sp1 could determine its effects (35, 36) . For instance, while a high rate of activation could permit the transcription of a large spectrum of pro and anti-apoptotic genes, low levels of activation could restrict the transcription to few pro-apoptotic genes. In 
